# OnCo record lomond-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/lomond-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "lomond-therapeutics" ;
  schema:name "Lomond Therapeutics"@en ;
  schema:alternateName "Lomond Therapeutics Holdings, Inc."@en ;
  schema:description "Lomond Therapeutics is developing two tablets for blood cancers: lomonitinib, which blocks the FLT3 and IRAK4 proteins in acute myeloid leukaemia, and lonitoclax, which blocks BCL-2 in chronic lymphocytic leukaemia and acute myeloid leukaemia. Both are in early trials."@en ;
  schema:url <https://onco.cc/companies/lomond-therapeutics/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001900520>, <https://www.sec.gov/Archives/edgar/data/1900520/000121390026044136/ea0283646-10k_lomond.htm>, <https://clinicaltrials.gov/study/NCT06366789>, <https://clinicaltrials.gov/study/NCT06708897>, <https://clinicaltrials.gov/study/NCT07303660> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/mds/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/bcl2-inhibitors/> ;
  onco:targets <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/bcl2/> .